Paroxetine Mesylate as a Multi-Target Anticancer Agent in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) is one of the most prevalent and deadly malignancies worldwide, with metastatic disease accounting for much of its high mortality. Despite the introduction of targeted therapies, such as anti-EGFR and anti-VEGFR monoclonal antibodies, incremental benefits often come at high cost and with the risk of drug resistance (paper). Recent attention has shifted toward drug repositioning—repurposing approved drugs with known safety profiles for new therapeutic indications. Among candidates, antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), have shown promise in preclinical cancer models. However, the precise mechanisms underlying their anticancer effects have remained unclear. The study by Jang et al. addresses whether paroxetine, a well-characterized SSRI, exerts cytotoxic and antitumor effects in human CRC cells and elucidates the molecular pathways involved in these actions (paper).

Key Innovation from the Reference Study

The central innovation of this work is the demonstration that paroxetine, beyond its established role as a selective serotonin reuptake inhibitor, directly inhibits two critical receptor tyrosine kinases—MET and ERBB3—in colorectal cancer cells. This dual inhibition suppresses downstream proliferative and survival signaling pathways, including AKT, ERK, and p38, while activating pro-apoptotic mediators such as JNK and caspase-3 (paper). By mechanistically linking paroxetine's anticancer activity to these kinases, the study provides a rationale for its repositioning as a targeted therapy in CRC.

Methods and Experimental Design Insights

Jang et al. employed a multifaceted approach to evaluate paroxetine’s anticancer effects:

• In vitro assays: Human CRC cell lines (HCT116 and HT-29) were treated with paroxetine. Cell viability was assessed using MTT assays, while colony and 3D spheroid formation assays gauged long-term proliferative capacity (paper).
• Apoptosis analysis: Apoptotic cell death was quantified by flow cytometry and confirmed via caspase-3 activation.
• Signaling pathway interrogation: Western blotting tracked phosphorylation status of MET, ERBB3, AKT, ERK, p38, and JNK following paroxetine exposure.
• In vivo validation: HT-29 xenografts in athymic nude mice were treated with paroxetine to assess tumor growth inhibition in a physiologically relevant model (paper).

This combination of in vitro and in vivo experiments allowed comprehensive mechanistic and translational evaluation.

Protocol Parameters

• cell viability assay | 7–26 μM (IC₅₀) | HCT116 and HT-29 colorectal cancer cells | Range of paroxetine concentrations inhibiting proliferation | paper
• apoptosis induction | significant at ≥10 μM | HCT116 and HT-29 | Apoptosis confirmed by flow cytometry and caspase-3 cleavage | paper
• colony/spheroid inhibition | 10–25 μM | HCT116 and HT-29 | Suppression of long-term clonogenicity and 3D tumor growth | paper
• xenograft tumor inhibition | paroxetine 10 mg/kg, i.p., daily | HT-29 mouse xenograft model | Significant tumor volume reduction | paper
• workflow suggestion | 5–20 μM for mechanistic studies | CRC cell line models | Enables pathway dissection while minimizing toxicity | workflow_recommendation

Core Findings and Why They Matter

Paroxetine treatment led to a dose-dependent reduction in CRC cell viability, accompanied by increased apoptosis and marked inhibition of colony and spheroid formation (paper). Mechanistically, paroxetine suppressed phosphorylation of the receptor tyrosine kinases MET and ERBB3—both implicated in CRC progression and metastasis. Downstream, this resulted in attenuation of AKT, ERK, and p38 survival signals, while upregulating pro-apoptotic JNK and caspase-3 activities. Importantly, in vivo studies corroborated these findings, as paroxetine significantly reduced tumor growth in HT-29 xenografts without overt toxicity (paper). These effects were observed at concentrations overlapping with those used in clinical and preclinical settings for psychiatric disorders, supporting translational feasibility. The dual activity as a receptor tyrosine kinase MET inhibitor and ERBB3 kinase inhibitor distinguishes paroxetine from other SSRIs and standard cytotoxics. This multi-target profile may help overcome resistance mechanisms and broaden the therapeutic landscape for CRC. The study also highlights the relevance of drug repositioning, offering a cost- and time-efficient route to new oncology therapies using agents with established pharmacokinetics and safety data.

Comparison with Existing Internal Articles

Recent internal resources have addressed diverse research facets of paroxetine mesylate, including its kinase activity and assay optimization:

• "Paroxetine Mesylate: Mechanistic Advances in Cancer Research" explores the compound’s dual action as an SSRI and multi-kinase inhibitor, echoing the reference paper's findings on MET and ERBB3 inhibition. However, the internal article extends discussion to broader protocol strategies, whereas Jang et al. provide direct in vitro and in vivo evidence for anti-colorectal cancer activity.
• "Reliable SSRI for Cell Assays" offers practical guidance on deploying paroxetine mesylate in cell-based oncology workflows, highlighting reproducibility and validated assay conditions—complementary to the mechanistic data in the reference study.
• "Multi-Target Mechanisms and Assay Impact" provides a broader overview of the molecule’s pharmacological spectrum, including its role as a cytochrome P450 inhibitor (notably CYP2D6) and G protein-coupled receptor kinase 2 inhibitor. These aspects, while referenced in the product dossier, are not directly explored in the core reference study’s CRC context.

This landscape underscores the expanding research applications of paroxetine mesylate, with the reference study supplying foundational mechanistic evidence for its repurposing in oncology.

Limitations and Transferability

While the study offers compelling evidence for paroxetine’s anti-CRC effects, several limitations warrant consideration:

• Experiments were conducted in two CRC cell lines and a single in vivo xenograft model; further validation in genetically diverse patient-derived models is needed.
• The molecular mechanisms were probed in detail for MET and ERBB3, but paroxetine also has known activity as a cytochrome P450 inhibitor (notably CYP2D6) and may influence drug metabolism in vivo (product_spec). This complexity could affect translational outcomes.
• Dose–response relationships for antitumor effects overlap with, but may not fully match, those for psychiatric indications. Careful titration and toxicity assessment would be essential in any future clinical translation.

Despite these caveats, the mechanisms uncovered are highly relevant for further preclinical and translational research.

Research Support Resources

Researchers seeking to explore the anticancer mechanisms of paroxetine in CRC and related oncology models can leverage Paroxetine Mesylate (SKU C8698) for in vitro and in vivo workflows. Its well-characterized status as a selective serotonin reuptake inhibitor, alongside documented activity as a receptor tyrosine kinase MET inhibitor and ERBB3 kinase inhibitor, makes it suitable for integrative pharmacological studies. For protocol refinement and assay optimization, consult complementary resources such as the "Mechanistic Advances in Cancer Research" internal article for nuanced workflow strategies. When sourcing compounds, ensure proper storage conditions (−20°C) to maintain reagent stability (product_spec).